study of f-627 in women with breast cancer receiving myelotoxic chemotherapy

Conditions: Neutropenia; Breast Cancer

Summary: a phase i, dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of f-627 in female breast cancer patients who received up to 4 cycles of epirubicin and cyclophosphamide. 18 patients (6 patients each cohort) were assigned to three escalated dose cohorts of 80, 240 and 320 µg/kg.

a phase i, dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of f-627 in female breast cancer patients receiving 4 cycles of ec (epirubicin plus cyclophosphamide) chemotherapy. 18 patients (6 patients each cohort) were assigned to three sequential doses cohort of f-627 at the dose of 80, 240 and 320 µg/kg. the patients received chemotherapy (100 mg/m\^2 epirubicin and 600 mg/m\^2 cyclophosphamide) administrated by i.v. injection on day 1 and f-627 by s.c. injection on day 3 of each cycle for 4 cycles. if no dose-limiting toxicity (dlt) was observed in 6 patients during first cycle, the next cohort was escalated. blood samples were collected for completed blood counts with differential, serum f-627 concentration and safety evaluation at different point following f-672 injection. the decision to proceed to the next higher dose was made jointly by the sponsor's medical expert and the investigator based upon the review of safety data in the first cycle treatment.

Eligibility criteria:
inclusion criteria: 1. 18-75 years old. 2. female postoperative breast cancer patients who require adjuvant chemotherapy, and are planned to receive 4 cycles of ec chemotherapy; 3. east cooperative oncology group (ecog) performance 0-1. 4. absolute neutrophil count (anc) ≥ 2.0 × 10\^9/l, hemoglobin (hb) ≥ 11.0 g/dl, and platelets (plt) ≥ 100 × 10\^9/l prior to chemotherapy. 5. hepatic and renal function within the normal range;. 6. left ventricular ejection fraction (lvef) \> 50%. 7. willing to sign the informed consent form and able to comply with protocol requirements exclusion criteria: 1. women in pregnancy or breastfeeding; women of child-bearing potential have a positive pregnancy test result prior to the first dose; 2. life expectancy less than 12 months; 3. radiation therapy within 4 weeks prior to enrollment; 4. breast cancer patients who have received neoadjuvant chemotherapy before radical mastectomy; 5. prior bone marrow or stem cell transplant; 6. with other malignant tumors other than breast cancer; 7. have received granulocyte colony stimulating factor (g-csf) treatment within 6 weeks prior to enrollment; 8. diagnosed with acute congestive heart failure, cardiomyopathy, or myocardial infarction by clinical diagnosis, electrocardiograph (ecg) or other approaches; 9. with any disease that may cause splenomegaly; 10. with acute infection, chronic active hepatitis b within 1 year (unless patients tested negative for hbsag prior to enrollment), or hepatitis c; 11. history of tuberculosis (tb); history of tb exposure, unless negative for tuberculin test; tb patients undergoing treatment; or suspected tb evaluated by chest x-ray; 12. known human immunodeficiency virus (hiv) positive or acquired immune deficiency syndrome (aids); 13. with sickle cell anemia; 14. with alcohol or drug abuse that may affect the compliance with the study; 15. with known hypersensitivity to e. coli derived proteins, g-csf, or excipients; 16. has received any other investigational drug within 4 weeks prior to enrollment; 17. patients with diseases or symptoms unsuitable for participating in the clinical trial based on the investigator's judgment;